Fidelity MSCI Health Care Index ETF
FHLCDividend History
| Pay Date | Amount | Ex-Date | Record Date |
|---|---|---|---|
| June 23, 2026 | $0.26 | 2026-06-18 | 2026-06-18 |
| March 24, 2026 | $0.23 | 2026-03-20 | 2026-03-20 |
| December 23, 2025 | $0.27 | 2025-12-19 | 2025-12-19 |
| September 23, 2025 | $0.26 | 2025-09-19 | 2025-09-19 |
| June 24, 2025 | $0.26 | 2025-06-20 | 2025-06-20 |
Dividends Summary
- Consistent Payer: Fidelity MSCI Health Care Index ETF has rewarded shareholders with 54 dividend payments over the past 13 years.
- Total Returned Value: Investors who held FHLC shares during this period received a total of $9.48 per share in dividend income.
- Latest Payout: The most recent dividend of $0.26/share was paid 25 days ago, on June 23, 2026.
- Yield & Schedule: FHLC currently pays dividends quarterly with an annual yield of 1.30%.
- Dividend Growth: Since 2013, the dividend payout has grown by 471.7%, from $0.05 to $0.26.
Company News
The Fidelity MSCI Health Care Index ETF (FHLC) offers broad healthcare sector exposure with lower costs (0.08% expense ratio), higher dividend yield (1.3%), and lower volatility, making it suitable for conservative investors. The State Street SPDR S&P Biotech ETF (XBI) focuses on biotechnology with higher growth potential (89.3% 1-year return) bu...
Fidelity MSCI Health Care Index ETF (FHLC) and iShares Global Healthcare ETF (IXJ) are compared as healthcare investment options. FHLC offers lower costs (0.08% expense ratio) with domestic-only focus and stronger 5-year performance (10.6% annualized returns), while IXJ provides international diversification but charges higher fees (0.40%). The a...
The healthcare sector has gained momentum recently, with investors rushing to buy beaten-down stocks. The performance of major healthcare ETFs like XLV, VHT, IYH, and FHLC will depend on the upcoming earnings releases of big names like Pfizer, Merck, Amgen, AbbVie, Bristol Myers Squibb, and Eli Lilly.
Sector ETF report for FHLC
While the healthcare sector is expected to benefit from cutting-edge medicines, new drug approvals, technological advancements, and deal activities, it is expected to witness a modest earnings decline of 5.6% in the first quarter.
